Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 18/20 | 0.44 |
| ▸ | IDH2 | P48735 | 4/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127139 | 1.00 | IDH1 (0.44) | IDH1IDH2CCNT1 | |
| SCHEMBL19687174 | 0.81 | IDH1 (0.39) | IDH1IDH2 | |
| SCHEMBL19686518 | 0.81 | IDH1 (0.45) | IDH1IDH2CCNT1 | |
| SCHEMBL21143994 | 0.79 | IDH1 (0.49) | IDH1IDH2 | |
| SCHEMBL19687379 | 0.77 | IDH1 (0.42) | IDH1IDH2CCNT1 | |
| SCHEMBL31127119 | 0.77 | IDH1 (0.42) | IDH1IDH2CCNT1 | |
| SCHEMBL21143987 | 0.77 | IDH1 (0.43) | IDH1IDH2CCNT1 | |
| SCHEMBL19687158 | 0.77 | IDH1 (0.42) | IDH1IDH2CCNT1 | |
| SCHEMBL19687157 | 0.76 | IDH1 (0.40) | IDH1IDH2 | |
| SCHEMBL19686314 | 0.76 | KCNN2 (0.56) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20160152592-A1 | IMIDAZOLE DIKETONE COMPOUND AND USE THEREOF | HINOVA PHARMACEUTICALS INC. (CN) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885CCNT1 4771/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885CCNT1 4771/4885 |
| US-20160152592-A1 | IMIDAZOLE DIKETONE COMPOUND AND USE THEREOF | AR, CYP17A1, CYP19A1 | IDH1 676/4885IDH2 364/4885CCNT1 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.